Cargando…

Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa

INTRODUCTION: WHO recommends antiretroviral treatment (ART) for all HIV-positive individuals. This study evaluated the association between baseline CD4 count and attrition in a cohort of HIV positive adults initiating ART at three department of health (DOH) clinics routinely providing ART at baselin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bock, Peter, Fatti, Geoffrey, Ford, Nathan, Jennings, Karen, Kruger, James, Gunst, Colette, Louis, Françoise, Grobbelaar, Nelis, Shanaube, Kwame, Floyd, Sian, Grimwood, Ashraf, Hayes, Richard, Ayles, Helen, Fidler, Sarah, Beyers, Nulda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909512/
https://www.ncbi.nlm.nih.gov/pubmed/29672542
http://dx.doi.org/10.1371/journal.pone.0195127
_version_ 1783315914526031872
author Bock, Peter
Fatti, Geoffrey
Ford, Nathan
Jennings, Karen
Kruger, James
Gunst, Colette
Louis, Françoise
Grobbelaar, Nelis
Shanaube, Kwame
Floyd, Sian
Grimwood, Ashraf
Hayes, Richard
Ayles, Helen
Fidler, Sarah
Beyers, Nulda
author_facet Bock, Peter
Fatti, Geoffrey
Ford, Nathan
Jennings, Karen
Kruger, James
Gunst, Colette
Louis, Françoise
Grobbelaar, Nelis
Shanaube, Kwame
Floyd, Sian
Grimwood, Ashraf
Hayes, Richard
Ayles, Helen
Fidler, Sarah
Beyers, Nulda
author_sort Bock, Peter
collection PubMed
description INTRODUCTION: WHO recommends antiretroviral treatment (ART) for all HIV-positive individuals. This study evaluated the association between baseline CD4 count and attrition in a cohort of HIV positive adults initiating ART at three department of health (DOH) clinics routinely providing ART at baseline CD4 counts >500cells/μL for the HPTN 071 (PopART) trial. METHODS: All clients attending the DOH clinics were managed according to standard care guidelines with the exception that those starting ART outside of pertinent local guidelines signed research informed consent. DOH data on all HIV-positive adult clients recorded as having initiated ART between January 2014 and November 2015 at the three study clinics was analysed. Attrition, included clients lost to follow up or died, and was defined as ‘being three or more months late for an antiretroviral pharmacy pick-up appointment’. All clients were followed until attrition, transfer out or end May 2016. RESULTS: A total of 2423 clients with a median baseline CD4 count of 328 cells/μL (IQR 195–468) were included of whom 631 (26.0%) experienced attrition and 140 (5.8%) were TFO. Attrition was highest during the first six months of ART (IR 38.3/100 PY; 95% CI 34.8–42.1). Higher attrition was found amongst those with baseline CD4 counts > 500 cells/μL compared to those with baseline CD4 counts of 0–500 cells/μL (aHR 1.26, 95%CI 1.05 to 1.52) This finding was confirmed on subset analyses when restricted to individuals non-pregnant at baseline and when restricted to individuals with follow up of > 12months. CONCLUSIONS: Attrition in this study was high, particularly during the first six months of treatment. Attrition was highest amongst clients starting ART at baseline CD4 counts > 500 cells/μL. Strategies to improve retention amongst ART clients, particularly those starting ART at baseline CD4 counts >500cells/μL, need strengthening. Improved monitoring of clients moving in and out of ART care and between clinics will assist in better understanding attrition and ART coverage in high burden countries.
format Online
Article
Text
id pubmed-5909512
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-59095122018-05-05 Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa Bock, Peter Fatti, Geoffrey Ford, Nathan Jennings, Karen Kruger, James Gunst, Colette Louis, Françoise Grobbelaar, Nelis Shanaube, Kwame Floyd, Sian Grimwood, Ashraf Hayes, Richard Ayles, Helen Fidler, Sarah Beyers, Nulda PLoS One Research Article INTRODUCTION: WHO recommends antiretroviral treatment (ART) for all HIV-positive individuals. This study evaluated the association between baseline CD4 count and attrition in a cohort of HIV positive adults initiating ART at three department of health (DOH) clinics routinely providing ART at baseline CD4 counts >500cells/μL for the HPTN 071 (PopART) trial. METHODS: All clients attending the DOH clinics were managed according to standard care guidelines with the exception that those starting ART outside of pertinent local guidelines signed research informed consent. DOH data on all HIV-positive adult clients recorded as having initiated ART between January 2014 and November 2015 at the three study clinics was analysed. Attrition, included clients lost to follow up or died, and was defined as ‘being three or more months late for an antiretroviral pharmacy pick-up appointment’. All clients were followed until attrition, transfer out or end May 2016. RESULTS: A total of 2423 clients with a median baseline CD4 count of 328 cells/μL (IQR 195–468) were included of whom 631 (26.0%) experienced attrition and 140 (5.8%) were TFO. Attrition was highest during the first six months of ART (IR 38.3/100 PY; 95% CI 34.8–42.1). Higher attrition was found amongst those with baseline CD4 counts > 500 cells/μL compared to those with baseline CD4 counts of 0–500 cells/μL (aHR 1.26, 95%CI 1.05 to 1.52) This finding was confirmed on subset analyses when restricted to individuals non-pregnant at baseline and when restricted to individuals with follow up of > 12months. CONCLUSIONS: Attrition in this study was high, particularly during the first six months of treatment. Attrition was highest amongst clients starting ART at baseline CD4 counts > 500 cells/μL. Strategies to improve retention amongst ART clients, particularly those starting ART at baseline CD4 counts >500cells/μL, need strengthening. Improved monitoring of clients moving in and out of ART care and between clinics will assist in better understanding attrition and ART coverage in high burden countries. Public Library of Science 2018-04-19 /pmc/articles/PMC5909512/ /pubmed/29672542 http://dx.doi.org/10.1371/journal.pone.0195127 Text en © 2018 Bock et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Bock, Peter
Fatti, Geoffrey
Ford, Nathan
Jennings, Karen
Kruger, James
Gunst, Colette
Louis, Françoise
Grobbelaar, Nelis
Shanaube, Kwame
Floyd, Sian
Grimwood, Ashraf
Hayes, Richard
Ayles, Helen
Fidler, Sarah
Beyers, Nulda
Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa
title Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa
title_full Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa
title_fullStr Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa
title_full_unstemmed Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa
title_short Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa
title_sort attrition when providing antiretroviral treatment at cd4 counts >500cells/μl at three government clinics included in the hptn 071 (popart) trial in south africa
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909512/
https://www.ncbi.nlm.nih.gov/pubmed/29672542
http://dx.doi.org/10.1371/journal.pone.0195127
work_keys_str_mv AT bockpeter attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica
AT fattigeoffrey attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica
AT fordnathan attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica
AT jenningskaren attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica
AT krugerjames attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica
AT gunstcolette attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica
AT louisfrancoise attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica
AT grobbelaarnelis attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica
AT shanaubekwame attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica
AT floydsian attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica
AT grimwoodashraf attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica
AT hayesrichard attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica
AT ayleshelen attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica
AT fidlersarah attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica
AT beyersnulda attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica
AT attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica